ArticlePharmacological reports : PR2025
Antiplatelet potencies of polysaccharides extracted from eight cultivated edible Pleurotus mushroom species.
Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginsenoside Rs3 (G-Rs3) inhibits agonist- and oxLDL-mediated platelet activation and attenuatesJournal of ginseng research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular diseases remain a leading global health challenge, necessitating effective antiplatelet therapies to mitigate thrombotic risks. Conventional antiplatelet agents, such as acetylsalicylic acid (ASA) and purinergic receptor type Y, subtype 12 (P2Y12) inhibitors, are effective but present limitations, including bleeding complications and resistance in some patients. This study investigates the antiplatelet potential of polysaccharide fractions extracted from fruiting bodies of eight different edible Pleurotus mushroom species cultivated for the purpose of this research.
methodsMushroom polysaccharide fractions were extracted from eight Pleurotus species (P. citrinopileatus, P. columbinus, P. djamor, P. eryngii, P. florida, P. ostreatus, P. pulmonarius, and P. sajor-caju) with cold water. Using multiple electrode aggregometry, we evaluated their inhibitory effects on platelet aggregation induced by adenosine-5'-diphosphate (ADP) and arachidonic acid (AA).
resultsPolysaccharides from all tested Pleurotus species exhibit significant inhibition of ADP-induced platelet aggregation in the 69-75% range, comparable to or exceeding that of ASA. While their beneficial effect on AA-induced aggregation was lower and limited to selected species with inhibition in the 6-46% range, polysaccharides from P. djamor and P. sajor-caju demonstrated promising dual inhibition.
conclusionsThis study suggests that Pleurotus-derived polysaccharides may serve as potential natural alternatives or adjuncts to existing antiplatelet therapies. Further in vivo studies and clinical trials are warranted to investigate their therapeutic potential in the prevention and management of cardiovascular disease.
Indexed as
Identifiers
40254695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.